Brain Neoplasms ; pathology ; physiopathology ; DNA Repair ; genetics ; Glioma ; pathology ; physiopathology ; Humans ; Statistics as Topic ; Targeted Gene Repair

DNA polymerase delta-interacting protein 38 (PDIP38) was identified in 2003 as a human DNA polymerase delta interacting protein which plays important roles in DNA repair, mitosis and vascular smooth muscle cells (VSMCs) migration. Our previous study showed that PDIP38 was expressed in mouse embryonic stem (ES) cells and upregulated in protein levels after differentiation from ES cells, while the expression in mRNA levels was not changed. We supposed that microRNA played key roles in the regulation of PDIP38 and the differentiation of ES cells. By bioinformatics assay, we predicted that PDIP38 was a potential target of microRNA--291a-5p (miR-291a-5p). Furthermore, we validated the possibility of miR-291a-5p to regulate the protein expression of PDIP38. Using luciferase reporter assay, realtime PCR and western blot methods, we firstly demonstrated that miR-291a-5p directly inhibited the expression of PDIP38. The present results shed a new light on the study of PDIP38 and miR-291a-5p in the differentiation of ES cells.
Animals ; Base Sequence ; DNA Repair ; Embryonic Stem Cells ; cytology ; Gene Targeting ; Mice ; MicroRNAs ; genetics ; Molecular Sequence Data ; Nuclear Proteins ; genetics ; Targeted Gene Repair

Pompe disease, also called type II glycogen storage disease, is a rare autosomal recessive inherited disease caused by the storage of glycogen in lysosome due to acid α-glucosidase (GAA) deficiency, with the most severe conditions in the skeletal muscle, the myocardium, and the smooth muscle. Patients may have the manifestations of dyspnea and dyskinesia, with or without hypertrophic cardiomyopathy. GAA gene mutation has ethnic and regional differences, and new mutation sites are found with the advances in research. Gene analysis is the gold standard for the diagnosis of Pompe disease. Conventional methods, such as skin and muscle biopsies and dried blood spot test, have certain limitations for the diagnosis of this disease. In recent years, prenatal diagnosis and newborn screening play an important role in early diagnosis of this disease. Enzyme replacement therapy (ERT) has a satisfactory effect in the treatment of this disease, but it may lead to immune intolerance. New targeted gene therapy and modified ERT will be put into practice in the future. This article reviews the research advances in the diagnosis and treatment of Pompe disease.
Animals ; Enzyme Replacement Therapy ; Glycogen Storage Disease Type II ; diagnosis ; enzymology ; genetics ; therapy ; Humans ; Targeted Gene Repair ; alpha-Glucosidases ; genetics ; metabolism